Multikinase inhibitors in thyroid cancer

Lisa Licitra, Laura D. Locati, Angela Greco, Roberta Granata, P. Bossi

Research output: Contribution to journalArticlepeer-review


Biological agents are rapidly developing for the treatment of metastatic RAI resistant thyroid cancer. The most promising results were shown by agents that target BRAF and VEGFR rather than RET. BRAF V600E mutation seems to be positively associated with tumour response by using BRAF targeting agents. With these agents impressive clinical responses and prolonged disease stabilisation were observed. This activity compares favourably with that of chemotherapy with less prominent toxicity, although typically associated drug side-effects should be promptly recognised and managed. To date no drug has proved to prolong survival, as such none of these agents has been approved.

Original languageEnglish
Pages (from-to)1012-1018
Number of pages7
JournalEuropean Journal of Cancer
Issue number6
Publication statusPublished - Apr 2010


  • Multikinase inhibitors
  • Thyroid cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Multikinase inhibitors in thyroid cancer'. Together they form a unique fingerprint.

Cite this